Tirzepatide is a novel medication that is FDA approved for the treatment of type 2 diabetes mellitus. It is composed of 39 amino acids and is an analog of the gastric inhibitory polypeptide. Given its potent weight loss properties, Tirzepatide can be used for obesity treatment. It works as a dual GLP-1 agonist and GIP agonist to maximize similar benefits that are seen with GLP-1 medications such as Semaglutide, and is given as a once-a-week subcutaneous injectable. The FDA approved Tirzepatide in May 2022. The main difference between Semaglutide and Tirzepatide is that Tirzepatide activates two hormone receptors – GLP-1 and GIP – while Semaglutide only activates GLP-1. This may give Tirzepatide a greater effect on blood glucose, appetite, and weight loss.
Core IV now offers Tirzepatide shots to assist patients who are trying to achieve weight loss goals. Tirzepatide is also known as Mounjoro, but we are offering our own compound.
What is a Tirzepatide shot?
At Core IV we are offering Tirzepatide to help unlocks the power of weight loss. It was developed with cutting-edge technology that works on two receptors at the same time instead of only one. Tirzepatide has been backed by rigorous clinical research, and is a game-changer in weight loss because its unique blend of ingredients helps to curb cravings, increase metabolism, helps you feel fuller longer which promote healthy weight loss, making it the perfect solution for those who want to achieve their weight loss goals quickly and effectively. Tirzepatide, can help you be on your way to a healthier, happier you in no time.
Week 1 through Week 4 2.5 mg once weekly 2.5 mg $200/shot Package of 4 $720
Week 2 through Week 8 5 mg once weekly 5 mg $300/shot Package of 4 $1,080
Week 9 through week 12 7.5 mg once weekly 7.5 mg $400/shot Package of 4 $1,440
Week 13 through week 16 10 mg once weekly 10 mg $500/shot Package of 4 $1,800
Week 17 through week 20 12.5 mg once weekly 12.5 mg $600/shot Package of 4 $2,160
Week 21 through week 24 15 mg once weekly 15 mg $700/shot Package of 4 $2,520
Nausea
Vomiting
Diarrhea
Decreased Appetite
Constipation
Abdominal Pain
Mounjoro is the brand name, whereas Tirzepatide is the name of the actual medication itself. As a result, the effects are basically the same.
Patients should be aware of the following contraindications. If either of these conditions have been recorded in either your personal history or your family history, you should avoid taking Tirzepatide:
Medullary Thyroid Cancer
Multiple Endocrine Neoplasia Syndrome Type 2
Our services do not take the place of your physician’s advice. These statements have not been evaluated by the FDA. As with any new treatment, please consult your physician if you have any concerns or to see if this is right for you.
Free call 24/7
+1-866-4 CORE iV
Copyright © 2021 Core IV Therapy, LLC | All Rights Reserved.